How the DSCSA supports the growth of biologics
by Maureen Perroni, on March 7, 2016
The growing availability of biologics is an important development in the pharmaceutical industry. These drugs, which are derived from living cells, have the potential to treat a whole host of difficult ailments. They're also being created quickly.
According to a Morningstar study, reported by the Economist, American pharmaceutical companies are currently developing more than 900 biologics to treat more than 100 diseases, and the market for these drugs continues to grow.
But shipping biologics to care providers and patients around the world is more difficult than shipping chemical-based drugs. That's because biologics need to be stored with strict temperature control in order to be effective, according to an article in The Journal of Commerce. This applies whether they are being sent to cold northern Europe or sweltering southern India.
New regulations are taking this difficulty into account. Passed in 2013 and expected to be fully implemented by 2023, the Drug Supply Chain Security Act is establishing a pharmaceutical track-and-trace system with new standards for consistency. This will make it easier for all parties in the supply chain to exchange information about each individual package - ensuring that each individual drug is stored in the manner that is necessary for it to remain effective.
It is important for the pharmaceutical industry to use serialized pharmaceutical labels that comply with the DSCSA. An Enterprise Labeling Solution can replace error-prone and often duplicative manual labeling efforts with a centralized system that can quickly and efficiently respond to necessary changes. Consistent labeling will ensure that all drug packages contain the information they need, from the first mile of the supple chain, to the last.
For more informatoin on the benefits of Enterprise Labeling for the pharmaceutical industry download this on demand webinar today.